PRO Medicus (ASX:PME) in Focus: Could This ASX Healthcare Stock Be One to Watch in September 2026?

Sonal Goyal

11 September 2026 05:29 PM AEST

PRO Medicus (ASX:PME) in Focus: Could This ASX Healthcare Stock Be One to Watch in September 2026?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

PRO Medicus (ASX:PME) remains one of Australia’s leading healthcare technology companies, providing medical imaging software solutions to hospitals, healthcare networks and radiology organisations.

The company continues expanding its presence in global healthcare markets, supported by long-term software contracts, technology adoption and Demand for digital healthcare solutions.

Company Overview

PRO Medicus develops medical imaging software used by hospitals, radiology groups and healthcare providers.

Its Visage platform supports medical image viewing, workflow management and healthcare information systems, helping clinicians access and analyse diagnostic images.

The company has a strong presence in North America, with additional operations in Australia and Europe.

FY26 Performance

PRO Medicus reported FY26 results for the year ended 30 June 2026, showing continued growth across its business.

Revenue increased to A$261.7 million, while underlying Earnings before interest and tax rose to A$196.1 million.

The company also reported higher underlying net profit and increased its fully franked dividend, reflecting continued earnings growth.

Operational Focus

PRO Medicus continues investing in healthcare technology, including digital pathology and artificial intelligence-enabled solutions.

The company remains focused on expanding its software capabilities while maintaining service quality for large healthcare customers.

A significant portion of its growth strategy is centred on increasing adoption of its platform in international healthcare markets.

Factors to Watch

Investors are expected to monitor new contract wins, implementation progress and adoption of additional healthcare technology solutions.

Key areas of focus include expansion in North America, growth in digital pathology and the company’s ability to maintain strong operating margins.

The timing of customer implementations will also remain important, as contracted Revenue is generally recognised over the life of agreements.

Risks

PRO Medicus operates in a competitive healthcare software market where technology innovation and customer relationships are important.

The company’s reliance on large healthcare customers means contract timing and renewals can influence revenue growth.

Currency movements, particularly due to international operations, may also affect reported results.

Conclusion

PRO Medicus continues to demonstrate growth through its medical imaging software platform, supported by healthcare technology adoption and long-term customer agreements.

The company’s future performance will depend on converting its contract pipeline into revenue, expanding internationally and maintaining its technology leadership. For investors following ASX healthcare stocks, PRO Medicus remains a key company to monitor.

FAQs

Q: What does PRO Medicus do?

A:PRO Medicus develops medical imaging software solutions used by hospitals, radiology groups and healthcare providers.

Q: Which markets are important for PRO Medicus?

A:North America is the company’s key market, supported by operations in Australia and Europe.

Q: What were PRO Medicus’ key FY26 financial results?

A:PRO Medicus reported FY26 revenue of A$261.7 million and underlying EBIT of A$196.1 million.

Q: What are the main risks for PRO Medicus?

A:Key risks include healthcare technology competition, customer concentration, implementation timing and currency movements.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.